Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Triple Negative Breast Neoplasms Clear all
Completed Phase 1Phase 2 Interventional Results available

Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

NCT03853707
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Atezolizumab, Capecitabine, Carboplatin, Ipatasertib, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jul 21, 2026, 3:23 PM EDT
Recruiting No phase listed Observational

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT04981119
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer, CRC, NSCLC, Pancreas Cancer, Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Mesothelioma, Malignant, Mesothelioma; Lung, Cancer, Triple Negative Breast Cancer (TNBC), Renal Cell Carcinoma (Kidney Cancer), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
Other · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
16
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 21, 2026, 3:23 PM EDT
Recruiting Phase 2 Interventional

Sacituzumab Govitecan In TNBC

NCT04230109
View directory record Official record
Conditions
Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions
Sacituzumab Govitecan, Pembrolizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Results available

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

NCT02719691
View directory record Official record
Conditions
Metastatic Breast Cancer, Solid Tumors
Interventions
Alisertib, MLN0128
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

NCT00483223
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, carboplatin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Jul 21, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

NCT04030507
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Interventions
MRI
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 21, 2026, 3:23 PM EDT
Not listed Phase 2 Interventional Results available

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

NCT03044730
View directory record Official record
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jul 21, 2026, 3:23 PM EDT
Terminated Phase 1 Interventional

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

NCT02419495
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
Interventions
Capecitabine, Carboplatin, Cyclophosphamide, Doxorubicin, Eribulin, Fluorouracil, Ipilimumab, Irinotecan Hydrochloride, Leucovorin Calcium, Nivolumab, Olaparib, Oxaliplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Selinexor, Topotecan
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 1 Interventional Results available

A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy

NCT03542175
View directory record Official record
Conditions
Breast Cancer
Interventions
Rucaparib, Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Norwalk, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

NCT00813956
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
gemcitabine plus carboplatin plus BSI-201
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Jul 21, 2026, 3:23 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 21, 2026, 3:23 PM EDT
Active, not recruiting No phase listed Observational

Comparison of the Breast Tumor Microenvironment

NCT03165487
View directory record Official record
Conditions
Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
Breast tissue collection, Blood sample collection
Other
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Jul 21, 2026, 3:23 PM EDT
Recruiting Phase 2 Interventional

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

NCT05846789
View directory record Official record
Conditions
Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer
Interventions
SOC Chemotherapy, Tocilizumab
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Atlanta, Georgia • Carmel, Indiana • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Jul 21, 2026, 3:23 PM EDT
Recruiting Phase 1 Interventional

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

NCT07137416
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Pidnarulex, Radiologic Imaging Procedure, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

NCT02162719
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Ipatasertib, Paclitaxel, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
17
States / cities
Fullerton, California • Los Angeles, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Jul 21, 2026, 3:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

NCT04180371
View directory record Official record
Conditions
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Interventions
BT5528, Nivolumab
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Encinitas, California • Orange, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 21, 2026, 3:23 PM EDT
Completed No phase listed Observational

Assessment of Candidate Protein Expression in Breast Cancer Specimens

NCT00918892
View directory record Official record
Conditions
Breast Cancer
Interventions
gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Jul 21, 2026, 3:23 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

NCT03941730
View directory record Official record
Conditions
Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Estradiol
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 3:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of PF-06873600 in People With Cancer

NCT03519178
View directory record Official record
Conditions
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions
PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

NCT00951054
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
NK012
Drug
Lead sponsor
Nippon Kayaku Co., Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 21, 2026, 3:23 PM EDT
Not listed No phase listed Observational

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

NCT05230186
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Tumor Biopsy
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Jul 21, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

NCT01104259
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Hereditary Breast/Ovarian Cancer - BRCA1, Hereditary Breast/Ovarian Cancer - BRCA2, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions
veliparib, cisplatin, vinorelbine tartrate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 21, 2026, 3:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

NCT02202746
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive, HER2, Estrogen Receptor Positive, ER, Triple Negative
Interventions
Lucitanib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
33
States / cities
Sedona, Arizona • Bakersfield, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Jul 21, 2026, 3:23 PM EDT